AstraZeneca Entered into a Research Collaboration with Illumina to Accelerate AI-based Drug Target Discovery
Shots:
- The companies collaborated to accelerate drug target discovery using AI-based genome interpretation & genomic analysis techniques. The collaboration focuses to improve the efficiency of pharma pipelines using industry-leading ability to identify genetic variants for human disease
- The collaboration will use Illumina's AI-based interpretation tools, PrimateAI & SpliceAI with AstraZeneca's analysis framework for rare variant genomic discoveries & its AI tools. AstraZeneca's Centre for Genomics Research will use the combined framework to analyze large-scale multi-omics data sets in its digital biobank
- The combined framework has the potential to prioritize drug candidates with an increased likelihood of approval across human diseases
Ref: PRNewswire | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
